Request Demo

Last update 10 Oct 2026

Bofanglutide

Last update 10 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Biological products

Synonyms

GZR-18, GZR18

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseRespiratory Diseases+ [1]

Active Indication

Sleep Apnea, ObstructiveHypoglycemiaDiabetes Mellitus, Type 2+ [1]

Inactive Indication-

Originator Organization

Gan & Lee Pharmaceuticals Co., Ltd.

Active Organization

Gan & Lee Pharmaceuticals Co., Ltd.

Gan & Lee Pharmaceutical Shandong Co. Ltd.

Inactive Organization-

License Organization

A.Menarini Industrie Farmaceutiche Riunite Srl

Lupin Ltd

JW PHARMACEUTICAL Corp.

+ [2]

Drug Highest PhaseNDA/BLA

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 1277323911

Source: *****

Clinical Trials associated with Bofanglutide

NCT07622810

/ Not yet recruitingPhase 3

BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and quality of life.
The main questions it aims to answer are:
Does Bofanglutide (GZR18) reduce body weight after 36 weeks of treatment compared with Semaglutide? What effects does Bofanglutide (GZR18) have on metabolic parameters, cardiovascular risk factors, and quality of life? How safe and well tolerated is treatment with Bofanglutide (GZR18)?
Researchers will compare Bofanglutide (GZR18) with Semaglutide, an active comparator, to evaluate efficacy and safety in adults with overweight or obesity.
Participants will:
Receive Bofanglutide (GZR18) every 2 weeks or Semaglutide once weekly by subcutaneous injection Follow standardized recommendations for diet and physical activity throughout the study Attend scheduled clinic visits for efficacy and safety assessments Participate in treatment and follow-up for up to 40 weeks, including screening, treatment, and safety follow-up periods

Start Date01 Sep 2026

Sponsor / Collaborator

Carnot Laboratorios

NCT07628985

/ Not yet recruitingPhase 3

BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer are:
Does Bofanglutide (GZR18) provide glycemic control comparable to Semaglutide based on changes in HbA1c? Is Bofanglutide (GZR18) safe and well tolerated in the study population? Can participants achieve glycemic targets and improve metabolic outcomes during treatment?
Researchers will compare participants receiving Bofanglutide (GZR18) with participants receiving Semaglutide to evaluate their effects on glycemic control, metabolic outcomes, safety, quality of life, and treatment satisfaction.
Participants will:
Be randomly assigned in a 1:1 ratio to receive Bofanglutide (GZR18) or Semaglutide.
Continue stable metformin monotherapy during the study. Receive subcutaneous study treatment with dose escalation according to the study protocol.
Participate in 30 weeks of active treatment. Attend scheduled study visits, laboratory assessments, and safety evaluations. Complete questionnaires related to quality of life and treatment satisfaction.

Start Date01 Sep 2026

Sponsor / Collaborator

Carnot Laboratorios

NCT07493057

/ Not yet recruitingPhase 3

A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea（OSA） Not Treated With Positive Airway Pressure（PAP）

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive airway pressure (PAP) therapy.

Start Date27 Apr 2026

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Bofanglutide

100 Translational Medicine associated with Bofanglutide

100 Patents (Medical) associated with Bofanglutide

Literatures (Medical) associated with Bofanglutide

01 Oct 2026·JOURNAL OF CHROMATOGRAPHY A

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application

Article

Author: Hung, Chi-Tat ; Leung, King-Kwong ; Tong, Lok-Hang

A rapid, sensitive, and selective multiplexed liquid chromatography-high-resolution mass spectrometry (LC-HRMS) method was developed and validated for the identification and quantitation of nine structurally diverse peptide-based glucagon-like peptide-1 receptor agonists (GLP-1 RAs): bofanglutide, ecnoglutide, exenatide, liraglutide, mazdutide, retatrutide, semaglutide, survodutide, and tirzepatide. These peptides represent single, dual, and triple receptor agonists, including four globally approved medications, two recently approved by China's National Medical Products Administration (NMPA), and three investigational drugs in Phase III clinical trials. Chromatographic separation was achieved on an ACQUITY Premier BEH C18 column (2.1 × 150 mm, 1.7 µm) at 50 °C using a multistep linear gradient with water and acetonitrile containing 0.1% difluoroacetic acid (DFA) and 0.5% dimethyl sulfoxide (DMSO) as mobile phases (flow rate 0.3 mL/min). The optimised method provided excellent resolution with baseline separation for most peptides within a 20-minute runtime. A key advantage of this work is the implementation of a dual strategy that combines high-resolution full-scan MS (HRMS) for accurate mass measurement with data-dependent HRMS/MS fragmentation for structural confirmation. Peptide identification adopted a top-down approach, achieving mass accuracy of 0.0-0.5 ppm and fragment ion coverage of 76-100%. The method showed good linearity (r² ≥ 0.995) over 4-235 ng/mL, with LODs of 0.44-2.06 ng/mL and LOQs of 8.29-11.74 ng/mL. It was successfully applied to marketed formulations of liraglutide, semaglutide, and tirzepatide using a simple dilute-and-shoot procedure, yielding mean recoveries of 113.7-118.4%. This LC-HRMS method offers superior selectivity and flexibility for analysing current and next-generation GLP-1 RAs.

01 Sep 2026·DIABETES RESEARCH AND CLINICAL PRACTICE

Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants

Article

Author: Lei, Chunpu ; Chen, Wei ; Liu, Long ; Zhang, Yining ; Liu, Xiaoyun ; Cheng, Xiaoqiang ; Tong, Yuanxu ; Dong, Junmin ; Zhao, Jing ; Hao, Xiaohua ; Li, Pu ; Min, Xiao

AIMS:

To evaluate the safety, relative bioavailability, pharmacokinetics (PK), and pharmacodynamics (PD) of oral bofanglutide (co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate [SNAC]) in healthy Chinese participants.

METHODS:

Part A enrolled 44 participants to receive single doses of oral bofanglutide (30, 60, or 90 mg) or subcutaneous bofanglutide injection (0.6 mg). Part B enrolled 48 participants to receive once-daily oral bofanglutide for 14 days (30 mg then 60 mg), with a post-dose fast of 30 or 60 min.

RESULTS:

Most treatment-emergent adverse events (AEs) related to oral bofanglutide were grade 1 gastrointestinal AEs; no serious AEs or severe hypoglycemia occurred. In Part A, single-dose relative bioavailability was 0.56% (30/60 mg) and 1.31% (90 mg). The maximum plasma concentration (C_max) and area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC_0-t) increased dose‑dependently from 40.95 to 254.47 ng/mL and from 3980.76 to 28180.67 h·ng/mL. In Part B, a 60‑minute post‑dose fast produced approximately twice the exposure of a 30‑minute fast, with apparent relative bioavailability of 9.22% vs. 4.88% (based on repeated-dose exposure with accumulation).

CONCLUSIONS:

Oral bofanglutide was safe and well tolerated. The PK/PD profiles support further investigation of once-daily oral bofanglutide for type 2 diabetes and overweight/obesity.

01 Aug 2026·ANNALS OF INTERNAL MEDICINE

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes

Article

Author: Lu, Li ; Chen, Wei ; Cheng, Zhifeng ; Liu, Jingyu ; Cai, Hanqing ; He, Anshun ; Xie, Tian ; Liu, Jinling ; Zheng, Yueyue ; Zhao, Jing ; Li, Yue ; Rodbard, Helena W. ; Liu, Ming ; Yang, Wei ; Wang, Su

BACKGROUND:

Bofanglutide is a novel glucagon-like peptide-1 receptor agonist under development for type 2 diabetes mellitus (T2DM) and overweight and obesity.

OBJECTIVE:

To evaluate the efficacy and safety of bofanglutide compared with semaglutide.

DESIGN:

Phase 2b, randomized, open-label, active-controlled trial. (ClinicalTrials.gov: NCT06256549).

SETTING:

Multicenter (37 sites in China).

PARTICIPANTS:

Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A_1c [HbA_1c], 7.0% to 11.0%).

INTERVENTION:

Participants were randomly assigned 1:1:1:1:1 to 1 of 5 treatment groups: bofanglutide titrated to targets of 12, 18, or 24 mg (biweekly [once every 2 weeks; Q2W]); bofanglutide titrated to 24 mg (once weekly [QW]); or semaglutide titrated to 1 mg QW.

MEASUREMENTS:

Change in HbA_1c level from baseline to week 24 (primary end point), secondary efficacy end points, and safety.

RESULTS:

Overall, 272 participants were enrolled, with a mean age of 50.8 years, HbA_1c level of 8.35%, and body mass index of 27.9 kg/m². At week 24, HbA_1c level change from baseline was -1.87% (95% CI, -2.11% to -1.63%), -2.28% (CI, -2.54% to -2.03%), and -1.94% (CI, -2.19% to -1.69%) for bofanglutide 12, 18, 24 mg Q2W, respectively; -2.32% (CI, -2.57% to -2.06%) for bofanglutide 24 mg QW; and -1.60% (CI, -1.85% to -1.35%) for 1 mg of semaglutide QW. Corresponding treatment differences versus semaglutide were -0.27% (CI, -0.61% to -0.08%), -0.68% (CI, -1.04% to -0.33%), -0.34% (CI, -0.70% to 0.02%), and -0.72% (CI, -1.08% to -0.36%), respectively. Gastrointestinal adverse events (GIAEs) (mostly grade 1 or 2 in severity) occurred in 81.8% to 87.3% and 51.9% of participants in the bofanglutide and semaglutide groups, respectively. Hypoglycemia occurred in 0% to 3.8% versus 1.9%, with no severe hypoglycemia.

LIMITATION:

Open-label, short duration, only Chinese participants.

CONCLUSION:

Meaningful reductions in HbA_1c levels were seen with bofanglutide in patients with T2DM; GIAEs were the most common and generally manageable.

PRIMARY FUNDING SOURCE:

Gan & Lee Pharmaceuticals.

News (Medical) associated with Bofanglutide

11 Sep 2026

·allsci.com

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I

China-based Gan & Lee Pharmaceuticals Co., Ltd. has dosed the first participant in a Phase I study of GZC8072, an oral peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) engineered for once-weekly administration. The candidate targets type 2 diabetes mellitus (T2DM) and weight management in people with obesity or overweight, and its entry into clinical testing adds to a field of oral GLP-1 agents. The study CTR20263271 is a multicenter, randomized, double-blind, placebo-controlled Phase I trial enrolling 112 participants. A single ascending dose (SAD) portion will evaluate safety and tolerability in healthy adults; a multiple ascending dose (MAD) portion will enroll participants with overweight or obesity. Primary endpoints cover safety and tolerability; pharmacokinetic and pharmacodynamic data will also be collected. GZC8072 is built on two proprietary platforms Gan & Lee calls NovaPeptide, intended to extend peptide half-life and support manufacturing, and SupOraTide, designed to improve oral bioavailability. The company said the combination yields enhanced intrinsic GLP-1 receptor activity, a prolonged pharmacokinetic half-life, and sufficient oral absorption to support weekly dosing. GZC8072 sits alongside bofanglutide (GZR18), a biweekly injectable GLP-1 RA currently in Phase III trials in China and Phase II in the US, and Insulin Ludefen (GZR4), an ultra-long-acting weekly basal insulin analog. GLP-1 is an incretin hormone secreted from intestinal L-cells that stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts centrally to reduce appetite. Its plasma half-life of roughly one to two minutes, owing to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), makes native GLP-1 clinically unusable without structural modification. Approved peptide GLP-1 RAs extend half-life through fatty acid conjugation enabling albumin binding — the basis for semaglutide's approximately 160-hour half-life — or through other stabilisation strategies. GZC8072 applies a distinct proprietary approach to achieve weekly oral dosing, though preclinical pharmacokinetic data have not been publicly disclosed. Oral semaglutide (Rybelsus), approved for T2DM, relies on the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate (SNAC) and requires fasting administration with limited water. The US FDA approved oral semaglutide tablets under the Wegovy brand for obesity management on December 22, 2025. Eli Lilly and Company's orforglipron (Foundayo), a non-peptide small-molecule GLP-1 RA, received FDA approval in April 2025. Notably, Innovent Biologics’ IBI3042, an oral non-peptide small-molecule GLP-1 receptor agonist also designed for once-weekly dosing that entered Phase I development in September 2026. IBI3042 also entered first-in-human testing earlier this month. GZC8072 therefore enters an emerging race to establish whether weekly oral GLP-1 dosing can be achieved, although its peptide-based approach distinguishes it from Innovent’s small-molecule strategy. Weekly oral dosing could differentiate GZC8072 from currently approved daily oral GLP-1 therapies, while retaining a peptide-based pharmacology distinct from small-molecule agonists such as orforglipron. Real-world adherence to injectable GLP-1 RAs at six months has been reported at 58–69%, supporting the rationale for more convenient oral formulations. Whether GZC8072's proprietary delivery platforms achieve bioavailability sufficient to produce clinically meaningful receptor engagement will be the central question Phase I pharmacokinetic data must answer. Spot something wrong? Report an issue with this article

Phase 1Drug ApprovalPhase 2PDCPhase 3

10 Sep 2026

·www.fiercebiotech.com

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide. Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release . Menarini will take over regulatory submissions and commercialization in a total of 39 countries, including the 27 European Union countries, the U.K., Switzerland, Norway, Iceland, Liechtenstein and the Balkan countries. “This partnership establishes a pivotal pathway for bofanglutide’s entry into the European market and marks another milestone in Gan & Lee’s transformation—from a leader in insulin to a global innovator in metabolic disease,” Wei Chen, Ph.D., chairman and CEO of Gan & Lee, said in a Sept. 3 statement. Bofanglutide is administered subcutaneously once every two weeks, requiring half the administration frequency of once-weekly GLP-1s. It completed a phase 3 study in China and a phase 2 study in the U.S. in patients who were overweight, obese or had Type 2 diabetes. Both studies met their primary endpoints, demonstrating weight loss and tolerability consistent with other GLP-1s. Gan & Lee plans to initiate a global phase 3 trial to support registration in Europe and other highly regulated markets. The deal comes two years after Gan & Lee announced that bofanglutide outperformed Novo Nordisk’s Ozempic (semaglutide) in reducing glycated hemoglobin (HbA1c) and body weight in a phase 2 trial of patients with Type 2 diabetes. While the partnership will extend Gan & Lee’s geographical reach, it is also designed to expand Menarini’s presence in the metabolic space and in innovative primary and specialty care sectors. Elcin Barker Ergun, group CEO of Menarini, noted that the deal will leverage Menarini’s capabilities in the region. “Clinical study results for bofanglutide so far have demonstrated weight reduction, secondary metabolic benefits and a safety profile consistent with expectations for this class, while its once-every-two-weeks dosing regimen offers an opportunity for differentiation,” he said. The content above comes from the network. if any infringement, please contact us to modify.

License out/inClinical Result

09 Sep 2026

·www.prnewswire.com

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA formulated for once-weekly administration. This milestone marks the formal entry of this innovative candidate into clinical development. The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase 1 study (CTR20263271), designed to evaluate the safety and tolerability of GZC8072 in healthy adult participants in the single ascending dose (SAD) portion and in participants with overweight or obesity in the multiple ascending dose (MAD) portion. A total of 112 participants are planned for enrollment, and will receive either GZC8072 tablets or matching placebo. About GZC8072 Tablets GZC8072 is a novel ultra-long-acting oral peptide GLP-1 RA independently developed by Gan&Lee based on native GLP-1 and designed for once-weekly administration. It is being developed for the treatment of type 2 diabetes mellitus (T2DM) and for weight management in people with obesity or overweight. GZC8072 is underpinned by two proprietary technology platforms — NovaPeptide™, designed to address the challenges of long‑acting peptide development and manufacturing, and SupOraTide™, designed to overcome key barriers to oral peptide delivery. The combined use of these platforms enables GZC8072 to achieve enhanced intrinsic activity, a prolonged pharmacokinetic half‑life, and significantly improved oral bioavailability, supporting a convenient once‑weekly oral dosing regimen. Currently, the global development program for GZC8072 tablets has progressed into Phase 1 clinical studies, with intended therapeutic indications covering T2DM and weight management in patients with obesity or overweight. Addressing Global Weight Management Needs with Oral Long-Acting Peptide Therapies Obesity is a chronic disease associated with a broad range of comorbidities and has become a major public health crisis worldwide. According to the World Health Organization, approximately 2.5 billion adults were overweight in 2022[1], and projections indicate this number will exceed 2.9 billion by 2030[2]. In this context, extending the duration of action and improving dosing convenience have become important areas of innovation in metabolic disease R&D. The treatment landscape is rapidly evolving - from long‑acting injectables to once-weekly oral formulations - reflecting the demand for patient‑centric options. From Long-Acting Injectables to Once-Weekly Oral Formulations: Expanding Innovative Therapies Gan&Lee, with extensive expertise in metabolic disorders, continues to advance its pipeline with a focus on long-acting therapies and greater dosing convenience. Its product portfolio continues to expand, including biweekly injectable bofanglutide (GZR18), ultra-long-acting weekly Insulin Ludefen (GZR4), and GZC8072 tablets — a once-weekly oral formulation that has now entered clinical development. The clinical initiation of GZC8072 marks a key milestone for the company's weight management franchise. Moving forward, the company will continue to develop more convenient therapeutic regimens leveraging its proprietary technology platforms to expand treatment options for patients. References: 1. 2. SOURCE Gan & Lee Pharmaceuticals 21% more press release views with Request a Demo

Phase 1

100 Deals associated with Bofanglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D13216	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 3	China	Gan & Lee Pharmaceuticals Co., Ltd.	27 Mar 2026
Hypoglycemia	Phase 3	China	Gan & Lee Pharmaceuticals Co., Ltd.	16 Jan 2025
Diabetes Mellitus, Type 2	Phase 3	China	Gan & Lee Pharmaceuticals Co., Ltd.	03 Jan 2025
Obesity	Phase 3	China	Gan & Lee Pharmaceuticals Co., Ltd.	17 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06256549 (Pubmed \| Ann Intern Med)	Phase 2	Diabetes Mellitus, Type 2	272	Bofanglutide 12mg Q2W	htgnwubhzi(azdiusjnst) = uhfbmwvbal qyaysouybd (dkgmlsdeyj, -2.11 to -1.63) View more	Positive	01 Aug 2026
				Bofanglutide 18mg Q2W	htgnwubhzi(azdiusjnst) = nlqgfqzpof qyaysouybd (dkgmlsdeyj, -2.54 to -2.03) View more
NCT06256523 (Pubmed \| Cell Rep Med)	Phase 1/2	Diabetes Mellitus, Type 2	72	GZR18	fvpgvcblye(qzstzzvvzu) = GZR18 is safe and well tolerated, with mostly mild-to-moderate gastrointestinal adverse events wgjuhhzmnr (ztxninscou )	Positive	01 Jul 2026
				Placebo
NCT06256536 (Pubmed \| Cell Rep Med)	Phase 1/2	Overweight \| Obesity	60	GZR18	ivohoowvfn(ejcksilubz) = dgmfdzffog kdgvstykpw (vscbnitirt )	Positive	01 Apr 2026
				Placebo	ivohoowvfn(ejcksilubz) = lwbmssnhue kdgvstykpw (vscbnitirt )
CTR20240663 (NEWS)	Phase 1	Diabetes Mellitus, Type 2	92	博凡格鲁肽片	kmgvhnjmsw(ypfwsgpgyy) = lsdcppmzbd piaunnysvf (kwpvpyogtq )	Positive	13 Nov 2024
CTR20232069 (NEWS) Manual	Phase 2	Diabetes Mellitus, Type 2	264	GZR18 (每两周给药一次)	membncbnpf(ozmetbwfmx) = xcpesvgpbm cqsypiegjp (rnxnzdtrmf ) View more	Positive	15 Oct 2024
				GZR18 (12 mg)	membncbnpf(thudccaivy) = qkbdqqvmhz ypwoxxpexp (nsidczbnsv )
CTR20231695 (PRNewswire) Manual	Phase 2	Overweight \| Obesity	-	GZR18 12 mg Q2W	praoorqzps(gzjoemtlwc) = drvwjcgotb oabzajfxyh (bjahyulefo )	Positive	22 Jul 2024
				GZR18 18 mg Q2W	praoorqzps(gzjoemtlwc) = gnrbehmflz oabzajfxyh (bjahyulefo )
NCT06256536 (ADA2024) Manual	Phase 1/2	Obesity	35	GZR18 30 mg QW	sfqydycbep(xfhkwjalcr) = iqqpisqdfx iwripsrapn (oadzdoqofc, -21.8 to -13.9) View more	Positive	21 Jun 2024
				GZR18 30 mg Q2W	sfqydycbep(xfhkwjalcr) = depodittmt iwripsrapn (oadzdoqofc, -17.5 to -8.0) View more
CTR20221509 (NEWS)	Phase 1/2	Diabetes Mellitus, Type 2	-	博凡格鲁肽	cuugyacgnr(irpgzilybb) = Clinical results have reached the endpoint twzyfuqcrk (etmsktzyif ) View more	Positive	15 May 2024
				安慰剂

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis